The Pharma Data

APRIL 27, 2022

1-4 Low HER2 expression occurs in both HR-positive and HR-negative disease. 6 Currently chemotherapy remains the only treatment option for patients with HR-positive tumours following progression on endocrine (hormone) therapy. 7 Few targeted options are available for those who are HR-negative.

HR 52

HR Trials Protein Medicine 52

The Pharma Data

NOVEMBER 16, 2020

Cases with knee replacement (KR) or hip replacement (HR) between 2014 and 2018 were identified; each case was age- and gender-matched with up to four controls (913 cases and 3,652 controls, respectively). The relation of warfarin versus direct oral anticoagulant (DOAC) use with the risk for KR or HR was assessed.

HR 52

HR Protein Medicine Research 52

XTalks

FEBRUARY 7, 2023

HR+/HER2- breast cancer is the most common type of breast cancer, with the National Cancer Institute (NCI) estimating 287,850 new cases of female breast cancer in 2022 alone. Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options. months vs. 11.2

HR 52

HR Hormones FDA Approval Antibody 52

The Pharma Data

JUNE 26, 2021

Basel, June 23, 2021 — VISION data published today in The New England Journal of Medicine (NEJM) shows that 177 Lu-PSMA-617 plus standard of care (SOC) significantly improved both overall survival (HR = 0.62 [95% CI: 0.52?0.74]; months) and imaging-based progression-free survival (HR = 0.40 [99.2% 0.74]; P<0.001; median 15.3

Medicine 52

Medicine HR Hormones Protein 52

pharmaphorum

OCTOBER 14, 2021

The protein, Programmed Death-Ligand 1 (PD-L1), is found on the surface of many cells throughout the body. The approved treatment regime demonstrated superior overall survival (OS; HR=0.64 [95% CI, 0.50-0.81]; 0.81]; p=0.0001) and progression-free survival (PFS; HR=0.62 [95% CI, 0.50-0.77];

HR 45

HR Containment Protein Clinical Development 45

The Pharma Data

MARCH 20, 2021

Previous studies have suggested that detection of viral proteins in body fluids could be a rapid diagnostic method for severe acute respiratory syndrome (SARS) ( 19 – 21 ). Nucleocapsid protein from SARS patients was abundant enough to be detected in clinical samples using an ELISA approach ( 20 ). RESULTS AND DISCUSSION.

Protein 52

Protein Antibody Development RNA 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA in combination with chemotherapy (pac, nab-paclitaxel or gem/carbo) reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.49, 0.86]; p=0.0012), with a median PFS of 9.7 months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), 7.5), versus the same chemotherapy regimens alone in these patients. months [95% CI, 5.4-32.4]

Hormones 52

Hormones HR Trials Protein 52

The Pharma Data

MARCH 17, 2021

percent compared to ET alone – a statistically significant improvement in invasive disease-free survival for HR+, HER2- high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009). Accepted as ePoster – Adjuvant Systemic Therapy. Available on-demand on March 10, 2021. Selected for one of the three St.

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

MARCH 26, 2021

months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; PD-L1 staining is the process by which the PD-L1 protein is visualised during testing. months (HR=0.76, 95% CI: 0.54–1.09). months compared with chemotherapy (median OS=20.2 0.89; p=0.0106) in people with high PD-L1 expression (TC3 or IC3-wild-type [WT]). About Tecentriq.

HR 52

HR Protein Genomics Genome 52

pharmaphorum

JUNE 17, 2022

Developed by Pfizer, Paxlovid was granted emergency use authorization (EUA) to treat COVID-19 patients based on the EPIC-HR study which showed it reduced the risk of hospitalization or death by almost 90 percent. The active drug is nirmatrelvir, a protease inhibitor, which helps keep the SARS-CoV-2 protein from replicating.

Drugs 105

Drugs Clinical Trials Clinical Trials HR 105

The Pharma Data

JANUARY 14, 2021

HR (95% CI): 0.68. HR (95% CI): 0.54 (0.33, 0.87). HR (95% CI): 0.44 (0.25, 0.77). HR (95% CI): 0.58; (0.35, 0.95); p=0.027. HR (95% CI): 0.44 (0.25, 0.77). HR (95% CI): 0.58; (0.35, 0.95); p=0.027.

Trials 52

Trials HR Containment Development 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. 07.27.2022. 07.19.2022.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

pharmaphorum

DECEMBER 1, 2021

It was hailed as a potential game changer when the interim MOVE-OUT data emerged, but has since been eclipsed by a rival oral antiviral from Pfizer – Paxlovid – which achieved a much higher 89% reduction in hospitalisations or death in the phase 3 EPIC-HR trial.

Drugs 52

Drugs HR Protein Development 52

Trialfacts

SEPTEMBER 15, 2024

VIKTORIA-1 is a clinical trial aimed at evaluating gedatolisib, a new investigational drug for patients with HR+/HER2-, Stage 3 or 4 breast cancer. More Study Details Study Locations About the Study Breast cancer represents a significant challenge, and advancing treatment options is crucial for patients facing this disease.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Genetics 52

The Pharma Data

APRIL 26, 2022

In this trial, patients treated with the STRIDE regimen experienced a 22% reduction in the risk of death versus sorafenib (based on a hazard ratio [HR] of 0.78, 96.02% confidence interval [CI] 0.65-0.93; 0.93; p=0.0035).4 4 Nearly one in three (31%) patients were still alive at three years versus one in five (20%) for sorafenib.4.

Immune Response 52

Immune Response Trials Protein Antibody 52

The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. HR-positive breast cancer. GDC-0077 is our next generation investigational PI3K? Ipatasertib. Real world data.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

MAY 4, 2021

months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; months (HR=0.76, 95% CI: 0.54–1.09). PD-L1 is a protein expressed on tumour cells and tumour-infiltrating cells, which suppresses the immune response and enables tumour cells to avoid detection by binding to proteins on the surface of immune cells. receptors.

Protein 52

Protein HR In-Vitro Medicine 52

The Pharma Data

APRIL 7, 2021

months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; Trodelvy is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. months from 1.7 0.54; p<0.0001).

HR 52

HR Genotype FDA Approval Genotoxicity 52

XTalks

MARCH 22, 2021

Maverick’s COBRA platform is used to engineer protein-based therapies that target T cells in the tumor microenvironment to trigger their activation. The therapies are designed to induce T cell-mediated killing specifically at the tumor site while sparing healthy cells and tissue.

Life Science 110

Life Science Development Marketing Gene Expression 110

The Pharma Data

SEPTEMBER 19, 2020

months in median OS with Tecentriq plus nab-paclitaxel, compared with placebo plus nab-paclitaxel (hazard ratio [HR]=0.67; 95% CI: 0.53–0.86). The OS data showed a negative trend; however, the study was not powered for the secondary endpoint of OS, and OS data were immature at time of analysis (initial HR=1.55 [95% CI: 0.86-2.80]

HR 52

HR Medicine In-Vitro Development 52

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Price of Verzenio: The list price of Verzenio is $15,405.72 per month; however, the actual amount patients pay will largely depend on their insurance plan. For Kisqali, sales reached $1.5

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

SEPTEMBER 18, 2020

The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of death (overall survival [OS]) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; 0.76; p<0.0001), compared with sorafenib.

Medicine 52

Medicine HR In-Vitro Protein 52

The Pharma Data

SEPTEMBER 10, 2021

Patients treated with a short course of five cycles of tremelimumab, an anti-CTLA4 antibody, over 16 weeks in addition to Imfinzi and chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options (based on a hazard ratio [HR] of 0.77; 95% CI 0.65-0.92; 0.92; p=0.00304). Median OS was 14.0 Tremelimumab.

HR 52

HR Trials Medicine Immune Response 52

The Pharma Data

MARCH 23, 2021

For OS and PFS, KEYTRUDA plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; 0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; for the placebo arm, with a HR of 0.62 (95% CI, 0.49-0.78; for the placebo arm, with a HR of 0.86 (95% CI, 0.68-1.10).

HR 52

HR FDA Approval Containment Genomics 52

Pfizer

JANUARY 27, 2023

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.

Research 112

Research Vaccination Vaccine Drugs 112

The Pharma Data

FEBRUARY 8, 2021

With nearly four years of median follow-up, data from the final analysis of the Phase 3 TITAN study confirmed that ERLEADA ® plus ADT provided a statistically significant improvement in OS with a 35 percent reduction in risk of death versus ADT alone (HR 0.65; p<0.0001).

HR 52

HR Hormones Development Production 52

The Pharma Data

JUNE 26, 2021

The virus had originally been obtained from a person in Washington state with COVID-19, but as it was grown over time in the laboratory, it had acquired a mutation that led to a change of a single amino acid at position 484 in the virus’s spike protein. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell.

Antibody 52

Antibody Vaccine Vaccination Research 52

The Pharma Data

SEPTEMBER 28, 2021

In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the danger of disease recurrence or death (DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) Data from the IMpower010 trial were published simultaneously within the Lancet. 0.88) in people with Stage II-IIIA NSCLC whose tumours express PD-L1?1%,

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

The Pharma Data

AUGUST 3, 2021

The study showed that treatment with Tecentriq, following surgery and platinum-based chemotherapy, reduced the risk of disease recurrence or death (DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50-0.88) 0.88) in people with Stage II-IIIA NSCLC whose tumours express PD-L1?1%, 1%, compared with best supportive care (BSC). months for BSC.

HR 52

HR Antibody FDA Approval Development 52

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

AUGUST 9, 2021

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumours, including breast, gastric, lung and colorectal cancers. 3 HER2 protein overexpression may occur as a result of HER2 gene amplification and is often associated with aggressive disease and a poor prognosis in breast cancer.

Trials 52

Trials Medicine Development Clinical Trials 52

XTalks

MAY 2, 2024

The companies followed it up with a second BLA submission in patients with HR+, HER2– breast cancer that has been previously treated with systemic therapy. The PDUFA target action date for the breast cancer submission has been set for the first quarter of 2025.

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

The Pharma Data

JANUARY 15, 2021

In the DESTINY-Gastric01 trial, patients (n=126) in the Enhertu treatment arm had a 41% reduction in the risk of death versus patients (n=62) treated with chemotherapy (based on a hazard ratio [HR] of 0.59; 95% confidence interval [CI] 0.39-0.88; 4.3] (HR=0.47; 95% CI 0.31-0.71) months [95% CI 9.6-14.3] months [95% CI 6.9-10.7]

Medicine 52

Medicine Trials Antibody HR 52

Pfizer

DECEMBER 20, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 6.45 percent increase from the $9.13

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

APRIL 23, 2021

Results of the VIALE-A study showed Venclyxto plus azacitidine significantly reduced the risk of death by 34% (overall survival; OS), compared to azacitidine alone (HR=0.66; 95% CI: 0.52, 0.85; p<0.001). Venclyxto blocks the BCL-2 protein and works to help restore the process of apoptosis. The median OS was 14.7 months (95% CI: 11.9,

Medicine 40

Medicine In-Vitro Antibody Development 40

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. No dosage adjustment is needed in patients with mild renal impairment.

Marketing 75

Marketing Production Drugs Licensing 75